Safety Observation of the Japanese Encephalitis Vaccine Given With a Primary Immunization

Japanese Encephalitis Clinical Trial

Official title:

Safety Observation of the Vero Cell-derived Inactivated Japanese Encephalitis Vaccine (JEV-I) Given With Primary Immunization in a Large Amount of Healthy Children Aged 8 Months and Older

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06372665
• Other study ID #: CDB-IV-JE-025202301
• Status: Recruiting
• Start date: January 1, 2024
• Est. completion date: June 30, 2025

Study information

• Verified date: April 2024
• Source: Liaoning Chengda Biotechnology CO., LTD
• Contact: Li Tong
• Phone: +86 15811315908
• Email: 14877107[@]qq.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a single-arm, non-randomized, open-label post-marketing safety observation study. The purpose of this study is to investigate the safety of JEV-I given with primary immunization in a large amount of healthy children aged 8 months and older.

Description:

Healthy children aged 8 months and older who choose to receive the study vaccine for primary immunization at their own expense in Jiangsu Province will be invited to participate in this study. No study vaccine will be supplied or administered as part of this study, participants will be monitored following vaccine administration in clinical settings. The primary immunization program with JEV-I requires 2 intramuscular doses administered 7-10 days apart. All participants will be observed for the incidence of any adverse events (AEs) within 30 minutes and from 30 minutes to 7 days after each vaccination, including local and systemic reactions. Additionally, all participants will be observed for unsolicited AEs within 30 days after after each vaccination.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 28547
• Est. completion date: June 30, 2025
• Est. primary completion date: March 31, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 8 Months and older

Eligibility

Inclusion Criteria:

• Healthy children who have received the inactivated Japanese encephalitis vaccine.
• Legal guardian of the participants voluntarily participates in the clinical trial and signs an informed consent form.
• Legal guardian of the subject has the ability to understand the procedures of the study and accept all scheduled visits. Exclusion Criteria: -

Related Conditions & MeSH terms

• Encephalitis
• Encephalitis, Japanese
• Japanese Encephalitis

Locations

Country	Name	City	State
China	Jiangsu Provincial Center for Disease Control and Prevention	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Liaoning Chengda Biotechnology CO., LTD

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants Reporting Solicited Local and Systemic Adverse Events, and Unsolicited Adverse Events	Adverse events (AEs) are defined as all adverse medical events that occur in participants after receiving the investigational drug, which can manifest as symptoms, signs, diseases, or abnormal laboratory tests, but they may not necessarily have a causal relationship with the investigational drug.; Unsolicited AEs will be collected within 30 days after each dose of vaccine administration, while solicited adverse reactions will be collected within 30 minutes and 30 minutes to 7 days after each dose of vaccine administration. A structured form (pre-listed) will be used to record the local and systemic reactions collected below.; Local reactions: Pain; Induration; Ecchymosis (Redness); Pruritus; Rash; Systemic reactions: Headache; Courbature (not from injection site); Diarrhea; Dysphagia; Anorexia; Vomiting; Sickness; Cough; Dyspnea; Irritability; Sleepiness; Acute allergic reaction; Pain (not from injection site)	30 days following each vaccination